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It has been demonstrated (1, 2) that a number of antigen-nonspecific soluble 
factors exist that can transmit signals for growth and/or differentiation among 
lymphoid cells, particularly T  lymphocytes, and may play a  major role in  the 
regulation of the immune response.  Recent studies (3-5) in both murine and 
human systems have revealed that such antigen-nonspecific soluble factors also 
play  a  critical  role  in  regulating  the  proliferation  and  differentiation  of  B 
iymphocytes. 
We have attempted to delineate the minimal and optimal signals required for 
the induction of resting human B cells to proliferate as well as the signals required 
for  the  induction  of activated  B  cells  to  differentiate into  immunoglobulin- 
secreting cells (4,  5).  In this regard~ we have recently demonstrated (6-8) that 
Staphylococcus  aureus  Cowan I  (SAC)  1 or a  high concentration of antiimmuno- 
globulin  antibody that  interacts  with  the  B  cell surface immunoglobulin (slg) 
directly induces the proliferation of resting human B cells, while a less powerful 
slg-mediated  signal,  such  as  that  delivered  by  low  concentrations  of anti-Ig 
antibody, results in  the activation of B cells without subsequent proliferation. 
These activated B cells, presumably arrested in the G1 phase of the B cell cycle, 
were able to respond to exogeneous T  cell-derived B cell growth factor (BCGF), 
now designated B cell stimulatory factor (BSF) (9),  to enter the S phase of the 
cell cycle. These activated B cells can in turn be induced to differentiate into Ig- 
secreting cells by B cell differentiation factors (BCDF), originally referred to as 
T  cell-replacing factors (10). These BCDF have been shown to be biochemically 
separable from interleukin 2 (IL-2) and BSF (11-13). 
It  is  currently controversial  whether IL-2  exerts  a  direct  effect on  B  cell 
function. Certain reports (3,  14) state that it is unlikely that IL-2 directly affects 
B cells; however, other studies indicate that IL-2 has an important role in the 
J Abbrevmtions  used  in  this  paper:  AET,  2-aminoethylisothiouronium  bromide; BCDF,  B cell 
differentiation factor; BCGF, B cell growth factor; BSF, B cell stimulatory factor, EBV, Epstein-Barr 
virus; FACS, fluorescence-activated cell sorter; HTLV, human T cell leukemia virus; IL-2, interleukin 
2;  MLR,  mixed  lymphocyte  reaction; MNC,  mononuclear cell; PMA, phorbol myristate  acetate; 
PHA, phytohemagglutinin;  SAC, Staphylococcus aureus Cowan I; SDS-PAGE, sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis. 
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maximal induction of plaque-forming cells (15-18;  M. Peters, J. L. Butler, J. B. 
Margolick, T. L. Gerrard, C. A. Dinarello, and A. S. Fauci, manuscript submitted 
for publication). Although hairy cell leukemic cells, which have a  B cell pheno- 
type, have been reported to express the receptor for IL-2 as defined by the Tac 
antigen (19),  it  is  still  unclear whether normal  B  cells express  IL-2  receptors 
during activation and/or differentiation. In the present study, by using anti-Tac 
antibody for immunoprecipitation and radiolabeled IL-2 in binding studies, we 
have addressed the question of whether IL-2 receptors can be induced on normal 
human  B  cells  after  stimulation  and  whether  freshly established  B  cell  lines 
express IL-2 receptors.  We have also investigated the role of IL-2 receptors on 
the  proliferation  and  differentiation of B  cells  using  recombinant  IL-2.  Our 
results clearly demonstrate that normal activated B  cells and some B  cell lines 
express IL-2 receptors that may play a role in the proliferation and differentiation 
of these cells. 
Materials and Methods 
Reagents.  Anti-# antibody is the F(ab')2  fragment of goat heavy chain-specific anti- 
human IgM (Cappel  Laboratories, Cochranville, PA). SAC was obtained from Bethesda 
Research Laboratories (Gaithersburg, MD); phytohemagglutinin (PHA) was purchased 
from Wellcome Research Laboratories (Beckenham, England); phorbol myristate acetate 
(PMA) was obtained from Sigma Chemical Co. (St.  Louis, MO).  Affinity-purified IL-2 
and [3H]leu,lys-IL-2  were prepared as previously described (20).  Recombinant IL-2 (lot 
LP210) was obtained from Cetus Corp. (EmeryVille, CA). The recombinant IL-2 (21) was 
96%  pure  by sodium dodecyl sulfate-polyacrylamide gel  electrophoresis (SDS-PAGE) 
analysis  and contained <0.04  ng endotoxin/106 U.  Mouse ascites  containing anti-Tac 
monoclonai antibody was a generous gift from Dr. Thomas Waldmann, National Institutes 
of Health, Bethesda, MD. Mixed lymphocyte reaction (MLR) supernatant was prepared 
as previously described (10). BSF derived from a human T-T hybridoma cell line was the 
same preparation as previously described in detail (22). 
Cell Purification.  Human tonsils obtained at tonsillectomy from 6-22-yr-old patients 
with chronic tonsillitis were dispersed into single-cell suspensions, and mononuclear cells 
(MNC) were separated by the standard Hypaque-Ficoll gradient method. T cell-enriched 
populations were obtained by rosetting the cells with 2-aminoethylisothiouronium  (AET)- 
treated sheep erythrocytes. B cell-enriched populations were obtained by depletion of T 
cells and monocytes (6). These B cell-enriched suspensions  were further separated into 
fractions according to cell volume by the technique of counterflow centrifugation-elutria- 
tion as previously described (23). The smallest-sized  B cell fractions with a mean volume 
of 160-180 #m  s had the following profile: they were >90% sIg-positive as determined by 
fluorescence-activated cell sorter (FACS) analysis; they contained <0.2% T cells as deter- 
mined by either erythrocyte receptor-positive cells enumerated by rosetting the cells with 
AET-treated sheep erythrocytes, or by FACS analysis after staining the cells with anti- 
OKT3 monoclonal antibody (Ortho Diagnostic Systems, Inc., Raritan, NJ); they contained 
<0.1% of monocytes as determined by nonspecific esterase staining (23). In some experi- 
ments, the B cells were further depleted to T cells by another rosetting technique. Briefly, 
5.0 ×  107 double AET-rosetted tonsillar cells were pelleted and incubated with 25 #l of a 
1:10 dilution of the monoclonal antibody Leu-1  (Becton-Dickinson Monoclonal Center, 
Inc., Mountain View,  CA) for 45  min on ice. The cells were washed twice to remove 
excess monoclonal antibody and resuspended in 8 ml of RPMI 1640. In a 50-ml conical 
tube, the cells were combined with 6 ml of 5 gram-percent human albumin and 18 mt of 
2% ox erythrocytes that had been previously coated with affinity-purified  goat anti-mouse 
Ig (Boehringer Mannheim Biochemicals,  Indianapolis, IN) using chromic chloride. The 
cells were pelleted, incubated on ice for 45 min, resuspended gently, and centrifuged on 
Hypaque/Ficoll gradients  in  a  standard  fashion.  The  further  purified  B  cells  were MURAGUCH1  ET  AL.  183 
harvested  from the  interface.  The  resulting  B  cells  were  contaminated  by <1/1,000 
OKT3-positive cells as determined by immunofluorescence. 
Cell  Cultures.  For binding assays, cells (2-3  ×  10°/well)  were cultured  in  1 ml of 
complete medium that was RPMI 1640 medium supplemented with 10% fetal calf serum 
(FCS)  (M.  A.  Bioproducts,  Walkersville,  MD),  100  U/ml  penicillin,  and  100  #g/ml 
streptomycin in 16-mm-diam flat-bottomed tissue culture wells (3524; Costar, Data Pack- 
aging,  Cambridge,  MA).  For proliferation assays, cells at the densities indicated below 
were cultured in 0.2  ml of complete medium in flat-bottomed microtiter plates (Costar 
3597).  Cultures  were  pulsed after various periods  of time as indicated  with  1 #Ci  of 
[3H]thymidine (6.7  Ci/mM;  New England  Nuclear,  Boston,  MA), and incorporation of 
[3H]thymidine was measured by standard liquid scintillation counting techniques. For the 
determination of Ig production, cells were cultured in microtiter plates for various periods 
of time as indicated, and the amount of Ig in the cell-free supernatants was measured by 
an enzyme-linked immunosorbent assay (7).  In several experiments, cells were cultured 
with various concentrations of affinity-purified IL-2, recombinant IL-2, or MLR super- 
natant, as indicated. 
Cell Lines.  Epstein-Barr virus (EBV)-transformed B cell lines from normal individuals 
were established in this laboratory as previously described (24). Briefly, MNC were isolated 
from peripheral blood as described above, and T  cells were separated from B cells and 
monocytes by rosetting with AET erythrocytes. The rosette-negative fraction was then 
infected  with  EBV  using  a  modification  of the  technique  previously  described  (25). 
Supernatants from the B95-8 marmoset cell line were filtered through a  0.45-#m filter 
6  (Nalge Co., Rochester, NY), diluted fourfold, and incubated with 5 x  10  cells in a sterile 
12-  ×  74-mm tube (Falcon  Labware,  Oxnard,  CA) for  1 h  at  30°C.  Cells  were then 
washed three times and incubated in  1.5 ml of 10% FCS and RPMI  1640 containing 80 
#g/ml of gentamicin (Gibco Laboratories, Grand  Island,  NY).  Cyclosporin A  (Sandoz, 
East Hanover, N  J) was added to the incubating cells at a concentration of 0.5 #g/ml to 
promote  rapid  outgrowth  of EBV-transformed  cells  by suppressing  T  cell  inhibitory 
influences. Cells were fed with fresh medium after 7-10 d, and after ~3 wk they were 
transferred to  50-ml flasks (Costar) and  maintained  for 4  mo in  RPMI  1640  medium 
containing  FCS.  Assays for EBV nuclear  antigen  were kindly performed by Mr.  Gary 
Armstrong  (Food  and  Drug  Administration)  using  standard  antisera.  Gross  cellular 
morphology was assessed on Wright's stained cells. Human T cell leukemia virus (HTLV)- 
transformed B cell lines were established from patients with adult leukemia as previously 
described (26). 
Cell Staining.  Cell  staining with  monoclonal antibodies and data analysis were per- 
formed as previously described (6),  with certain modifications. To prevent Fc fragment 
binding,  cells  were  incubated  with  aggregated  human  IgG for  45  min  at  37°C,  and 
washed cells were allowed to react with  mouse ascites containing anti-Tac monoclonal 
antibody, control ascites (P3), or anti-OKT3, whose IgG isotype is matched to that of anti- 
Tac antibody (27). Fluorescein-conjugated F(ab')~ fragment of affinity-purified goat anti- 
mouse IgG (Tago, Inc., Burlingame, CA) was used as a developing antibody. In addition 
to  staining  with  monoclonal  antibody  reagents,  cells  were  also  directly  stained  with 
fluorescein-conjugated  F(ab')~  fragment  of goat  anti-human  Ig  (#,  %  and  a  chains) 
obtained from Cappel  Laboratories. Stained cells were analyzed by a  FACS  II.II (B-D 
FACS Systems, Mountain View, CA). 
Characterization  of Tac  Antigens.  Characterization  of Tac  antigens  on  cell  surface 
membranes was performed by electrophoretic transfer blotting. Cells (~ 107) were solubi- 
lized with  1% Nonidet P-40, and lysates were precleared with an isotype-matched mono- 
clonal  antibody  (anti-mouse  Igh-4a;  IgG2a-K;  Becton-Dickinson  Monoclonal  Centers, 
Inc.). Precleared lysates were immunoprecipitated with either anti-Tac or Leu-1 monocio- 
nal antibody, run on a  10% SDS gel, and electrophoretically transferred to nitrocellulose 
paper (28). Strips cut from the sheet were reacted with anti-Tac or Leu-1, washed, and 
incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (Bio-Rad Labo- 
ratories, Richmond, CA). The strips were then developed with 4-Cl-1  naphthol. Antigens 
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labeled with ~25I by the lactoperoxidase method (19).  Labeled cells were extracted, and 
supernatants were cleared with an isotype-matched monoclonal Ig (anti-mouse Igh-4a) 
and protein A-coupled Sepharose. Resulting supernatants were immunoprecipitated with 
anti-Tac antibody-conjugated protein A sepharose. The pellets were then boiled in 20% 
glycerol/1% 2-mercaptoethanol/l% SDS and analyzed by 10% SDS-PAGE. 
Binding  Assay of Radiolabeled IL-2.  The  IL-2 binding assay was performed by the 
method described by Robb et al. (20) and Smith (29). Briefly, to determine the level of 
binding, serial dilutions of [3H]leu,lys-IL-2 were incubated at 37°C with 106-107 cells in 
a  total volume of 100  IA  of RPMI  1640  supplemented with  10%  FCS  using  1.5-ml 
Eppendorf micro-test tubes (Brinkman Instruments, Westbury, NY). After 25 min, 1 ml 
of ice-cold  RPMI  1640-FCS was added to each tube, and the cells were spun down at 
10,000 g for 15 s in an Eppendorf model 5414 centrifuge. The supernatant was removed 
and counted by liquid scintillation to determine the unbound radioactivity. The cell pellet 
was resuspended in 100 ~1 RPMI 1640-FCS at 4°C, and the cell suspension was layered 
on a mixture of 84% silicone oil (550 fluid; Contour Chemical Co., North Reading, MA) 
and 16% paraffin oil (Fisher Scientific Co., Pittsburgh, PA) in a soft 400-#1 polyethylene 
tube (Bio-Rad Laboratories). After centrifugation at 10,000 g for 90 s, the tip containing 
the cell pellet was cut off and placed in scintillation vials, and the cell pellet was solubilized 
by the addition of 100 #1 of 1% SDS, followed by addition of 15 ml Biofluor (New England 
Nuclear). The level of nonsaturable binding was determined in the presence of 150-fold 
molar excess of unlabeled IL-2, and specific binding was calculated by subtracting the 
amount of the nonsaturable binding. 
Results 
Tac Expression on Normal Activated B Cells.  T  cells express Tac antigen, which 
is recognized by a  monoclonal antibody, anti-Tac, after activation by lectins or 
antigen (27,  30).  Subsequent studies (31) have revealed that this anti-Tac anti- 
body can recognize, at least in part, the IL-2 receptor expressed on the plasma 
membrane. To determine whether activated B cells express Tac antigen, freshly 
separated B cells were incubated with anti-# antibody for 3 d  and subsequently 
stained with anti-Tac monoclonal antibody. As a positive control for Tac expres- 
sion, purified T  cell populations were incubated with PHA and stained with the 
same antibody. To define T  cell populations, and also as a control for an isotype- 
matched monoclonal antibody to anti-Tac antibody (IgG2a-K), anti-OKT3 anti- 
body was  used  for  the  stainings.  As  expected,  the  majority (>80%)  of PHA- 
stimulated T  cell blasts were OKT3-Positive and Tac-positive (Fig.  1, A and B). 
Anti-#-activated  B  cells  were  also  Tac-positive  (30-40%)  but  OKT3-negative 
(Fig.  1, C and D). These activated B cells were also stained with anti-human Ig 
antibody to establish that they were in fact B cells. >90%  of cells were stained 
positively. We then investigated the induction of Tac antigen using other B cell 
activators,  PMA  or  SAC,  and  found that almost the same  proportions  of the 
activated B cells expressed Tac antigen with optimal concentrations of PMA and 
SAC (Table I). Kinetic studies revealed that Tac antigen was detected after a 24- 
h  incubation  of B  cells  with  anti-~,  PMA,  or SAC,  which  suggests  that  Tac 
antigen can indeed be induced on the surface membrane of normal B cells. 
Tac Expression  on  a  Panel of Established B  Cell Lines.  The observation  that 
normal activated B cells express Tac antigen on the cell surface membrane posed 
the possibility that freshly established B cell lines might also express this antigen. 
Thus, we examined the reactivity of anti-Tac antibody against a panel of human 
B  cell  lines  (Table  II).  We  found  that  anti-Tac  showed  weak  but  significant MURAGUCHI  ET  AL.  185 
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FIGURE  1.  FACS profiles of normal activated T  cells and B cells stained with monoclonal 
anti-Tac antibody. T cell blasts were prepared by activating T cells with PHA, and B cell blasts 
were obtained by activating B cells with anti-# antibody. Cells were stained by an  indirect 
method: cells were first treated with mouse control ascites, mouse monoclonal anti-OKT3 
antibody, or anti-Tac antibody followed by staining with fluorescein isothiocyanate-conjugated 
F(ab')2 fragment goat anti-mouse IgG;  PHA-activated T  cell blasts were stained with anti- 
OKT3 (A) or anti-Tac (B). Anti-v-activated B cell blasts were stained with anti-OKT3 (C) or 
anti-Tac (D). Stained cells were analyzed by FACS ll.II. Abscissa represents relative fluores- 
cence intensity and ordinate represents relative cell number in individual fuorescence  intensity 
channels. 
TABLE  I 
Tac Expression on Normal Activated Human B Cells 
Group  Cells*  Incubation  ~ 
Percent positive cells  ! 
OKT3  Tac  sIg 
A  T  PHA, 72 h  85%  93%  ND  I 
B  B  --, 0 h  <1  <1  92 
C  B  Anti-u, 24 h  <1  25  ND 
D  B  Anti-u, 48 h  <1  38  ND 
E  B  Anti-u, 72 h  <1  42  90 
F  B  PMA, 72 h  <1  54  93 
G  B  SAC, 72 h  <1  50  91 
* T  cells and B cells were separated from tonsillar MNC as described in 
Materials and Methods. 
* Cells were cultured with PHA (2 ug/ml), anti-u (100 ug/ml), PMA (50 
ng/ml), or SAC (1.5 x  104 vol/vol). 
0 Percent of positive cells was determined by  FACS  II.II.  Background 
(cells stained with control ascites) was subtracted. 
! ND, not done. 186  INTERLEUKIN  2  RECEPTORS  ON  HUMAN  B  CELLS 
TABLE II 
Tac Expression  on Established B Cell Lines 
Cell lines examined 
Surface  antigens 
slg*  Tac*  EBNA e  p19 ! 
FB9  ++  -  +  - 
SR  ++  -  +  - 
HT  ++  -  +  - 
AL  ++  -  +  - 
LE  ++  -  +  - 
AP  ++  +  +  - 
CB  ++  +  +  - 
HS1  ++  ++  -  + 
CS2  ++  ++  -  + 
*  Cells  were  stained  with  fluorescein  isothiocyanate-conjugated  (Fab')2 
fraction of anti-human Ig (~, ~,, a) antibody. 
* Cells were incubated with mouse anti-monoclonal  anti-Tac antibody 
followed by staining with fluorescein isothiocyanate-conjugated F(ab')2 
fraction of anti-mouse Ig. 
| EBV nuclear antigen  was detected  using standard  anti-EBV nuclear 
antigen sera. 
| p19, an  antigen that  is expressed on the  cell membrane of HTLV- 
infected cells, was examined by staining cells with anti-pl 9 antibody. 
reactivity to only two out of eight EBV-transformed B cell lines, which had been 
established from normal donors. Anti-Tac showed definite reactivity to two out 
of two B  cell lines  that  were infected by HTLV.  As reported by Longo et al. 
(26),  the  HS1  B  cell clone was  isolated from the peripheral blood of a  patient 
with adult T  cell leukemia and it contained integrated HTLV proviral sequences 
in its DNA and expressed HTLV-encoded virus protein on its cell membrane. 
The CS2 B cell clone was obtained from normal cord blood lymphocytes by co- 
culturing them with irradiated HS 1 cells. Representative FACS profiles of B cell 
lines stained with anti-Tac antibody are shown in Fig. 2. Taken as a whole, these 
data suggest that (a) some established B cell lines from normal donors express 
Tac antigen and (b) there is a  strong relationship between Tac expression and 
HTLV  infection in human B cells. 
Partial  Characterization  of Tac Antigen  on B  Cells.  Initial characterization of 
the cell surface Tac antigen on B cells was performed by electrophoretic transfer 
blotting  with  anti-Tac  antibody  as  well  as  immunoprecipitation  of  surface- 
iodinated cells with anti-Tac.  In electrophoretic transfer blotting with anti-Tac, 
a broad 50,000-55,000  mol wt band was obtained from both anti-~-activated B 
cells and PHA-stimulated T  cells (Fig. 3A, lanes a and b). However, in the same 
type of experiment using anti-Leu- 1 antibody, a 65,000 mol wt band was obtained 
only from PHA-stimulated T  cells but not from activated B cells (Fig.  3A, lanes 
c and d). When anti-~-activated normal B cells, HS1 cells, and PHA-stimulated 
T  cells were surface-iodinated and immunoprecipitated with anti-Tac (Fig.  3B, 
lanes a  and c), a  broad 50,000-58,000  mol wt band was obtained from normal 
activated B cells as well as HS 1 cells. These antigens were found to be essentially 
identical in size to that obtained from the membranes of normal activated T  cells 
(Fig. 3, lane b). MURAGUCHI  ET  AL.  187 
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FIGURE 2.  FACS profiles of B cell lines stained with monoclonal anti-Tac antibody. B cell 
lines were incubated with mouse control ascites or mouse anti-Tac antibody followed by the 
staining with fluorescein isothiocyanate-conjugated F(ab')~ fraction of goat anti-mouse IgG. 
Stained cells were analyzed by FACS lI.II. Abscissa represents relative fluorescence intensity, 
and ordinate represents relative cell number. (A) HTLV-infected B cell line, HS1; (B) EBV- 
infected B cell line, CB. 
Binding Assay oflL-2.  A binding assay using [SH]leu,lys-IL-2 was performed 
to  determine  the  number  and  affinity  of IL-2  receptors  on  B  cells  and  was 
compared with those expressed on PHA-stimulated T  cell blasts. It was demon- 
strated that the average number of receptors per anti-u-activated B cell was less 
than that of PHA-stimulated T  cell blasts (320 and 4,050 for B cells and T  cells, 
respectively) (Fig.  4).  It was also demonstrated  by Scatchard plot analysis that 
the affinity of IL-2 receptors on anti-#-activated  B cells was lower than that of 
PHA-T  cell blasts; dissociation constants obtained were 457 and  26 pM for B 
cells and T  cells, respectively (Fig. 4). Furthermore,  binding data of [3H]IL-2 to 
cloned HS 1 B cells and PHA-T cell blasts demonstrated that the average number 
of receptor binding sites per cell was 1,000 for HS 1 cells and 6,000 for PHA-T 
cell  blasts (Fig.  5).  A  Scatchard  plot of binding  of [~H]IL-2  to  HS1  cells and 
PHA-T  cell blasts  indicated  that  HS1  cells have much  lower affinity binding 
sites compared  with  PHA-T  cell blasts  (55  pM  for HS1  cells and  14  pM  for 
PHA-T cell blasts). Thus, these data demonstrate that both normal activated B 
cells and a B cell line have significantly fewer binding sites and lower affinity of 
IL-2 receptors as compared with PHA-stimulated T  cell blasts. 
Effects  of IL-2  on  Activation  and  Differentiation  of Normal  Human  B  Cells. 
Recombinant  IL-2  (21,  32)  was used  to investigate  the effects of IL-2  on  the 
proliferation  and  differentiation  of highly  purified  normal  human  tonsillar  B 188  INTERLEUKIN  2  RECEPTORS  ON  HUMAN  B  CELLS 
FIGURE 3.  (A) Electrophoretic transfer blotting of solubilized PHA-T cell blasts and anti-g- 
activated B cells with anti-Tac antibody and Leu-1 antibody. Solubilized cells were immuno- 
precipitated  with an  antibody  and  transferred to the  nitrocellulose paper as described  in 
Materials and Methods. Strips cut from the sheet were reacted  with the identical antibody, 
washed, and incubated with goat anti-mouse IgG. Blotting analysis of PHA-stimulated T cells 
with anti-Tac antibody (lane a); anti-g-activated  B cells with anti-Tac antibody (lane b); PHA- 
stimulated T cells with Leu-1 antibody (lane c); anti-g-activated  B cells with Leu-1 antibody 
(lane d). (B) SDS gel comparison of immunoprecipitation with anti-Tac antibody from normal 
activated B cell blasts, a B cell line, and normal activated T  cell blasts. Cells surface labeled 
with ~251 were  extracted  and  immunoprecipitated  with anti-Tac  antibody  as described  in 
Materials and  Methods. Antigen  immunoprecipitated  with anti-Tac  antibody  from PHA- 
stimulated T cells (lane a); with anti-u-activated  B cells (lane b); and with a B cell line, HS1 
(lane c) was analyzed.  Markers  used  in  these  experiments  were  phosphorylase b (92,500), 
albumin  (66,200),  ovalbumin  (45,000),  carbonic  anhydrase  (31,000),  and  soybean trypsin 
inhibitor (21,500). 
cells.  Tonsillar B  cells were activated in vitro for 2  d  with SAC, harvested, and 
recultured with various concentrations of recombinant IL-2. As shown in Fig. 6, 
recombinant  IL-2  enhanced  the  DNA  synthesis  of SAC-activated  B  cells  in  a 
dose-dependent manner. In data not shown, IL-2, in the absence of an activating 
signal,  did  not  induce  proliferation  of resting  tonsillar  B  cells (J.  H.  Kehrl,  A. 
Muraguchi,  and  A.  S.  Fauci,  manuscript in  preparation).  Thus,  IL-2, like BSF, 
can promote the growth of activated B cells. 
The BSF we studied previously promoted the growth but not the differentia- 
tion of activated B cells (4). To assess the effects of IL-2 on B cell differentiation, 
tonsillar  B  cells  were  activated  for  2  d  with  SAC  and  cultured  with  various 
concentrations of IL-2, and then the Ig content in the culture supernatants was 
measured after an additional 4 d of culture (Fig. 6). The addition of recombinant 
IL-2 to preactivated B cells induced significant IgG and IgM production.  These 
results  suggest  that  IL-2  can  act  directly  on  SAC-activated  B  cells  to  induce 
differentiation,  although  the possibility that  IL-2 stimulated  residual  T  cells to 
induce  a  pool  of lymphokines  that  secondarily  influenced  B  cell  function  re- 
mained a  possibility. 
To address this possibility, we cultured highly purified tonsillar B cells (<0.1% 
OKT3-positive) at various cell densities with or without recombinant IL-2. Even 
at very low cell densities,  IL-2 enhanced both DNA synthesis and Ig production 5OOO 
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of [SH]IL-2 to PHA-activated T  cell blasts.  T  cell blasts were prepared by incubating T  cells 
with PHA (2 #g/ml) for 3 d, and specific bindin[gs were determined. Insert depicts Scatchard 
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by tonsillar B cells (Table III). We conclude that IL-2 can directly act on IL-2 
receptor-bearing B cells to promote both their growth and differentiation. 
Effect of IL-2 on the Proliferation and Differentiation of the IL-2 Receptor-bearing 
B  Cell  Line  HS1.  To  study  the  effect of IL-2  on  the  proliferation  of IL-2 
receptor-bearing homogeneous B cells, cloned HS1  cells were incubated with 
recombinant IL-2 (10  -2 to 104 U/ml) for 3 d, and DNA synthesis was measured 
by incorporation of [3H]thymldine. IL-2 at high concentrations induced signifi- 
cant enhancement of proliferation of HS1  cells in  a  dose-dependent manner 
(Fig.  7A). The decrease in proliferation noted at the highest concentration of 
recombinant IL-2 may be due to buffer toxicity (K. Koths, Cetus Corp., personal 
communication). Importantly, this  IL-2-induced enhancement of proliferation 
of HS 1 cells was inhibited by the addition of anti-Tac antibody but not control 190  INTERLEUKIN  2  RECEPTORS  ON  HUMAN  B  CELLS 
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ascites to the culture (Fig. 7B). The effect of IL-2 on Ig production was assessed 
by incubating HS1 cells with various concentrations of recombinant IL-2 followed 
by measuring  the  amount  of Ig secreted in  the  supernatant  on  day 3.  It  was 
found that  HS1  cells were spontaneously producing IgM (~800 ng/ml  per  10 4 
cells) but no IgG or IgA in the absence of IL-2 and that only minimal enhance- 
ment  of IgM  production  or  induction  of IgG  and  IgA  was  observed  in  the 
presence  of IL-2  (data  not shown).  These data demonstrate  that  IL-2 at  high 
concentrations can enhance the growth of HS 1 cells but has limited effects on 
Ig production in these cells. 
Discussion 
The present study has demonstrated that  IL-2 receptors in the form of Tac 
antigen  expression  could  be  induced  in  normal  human  B  cells after  in  vitro MURAGUCHI  ET  AL.  191 
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TABLE  III 
IL-2 Promotes the Growth and Differentiation of In Vitro Activated Human B Lymphocytes at 
Low Cell Densities* 
Cell number  DNA synthesis*  IgG productions  0 
(  x 10-~/well)  -  IL-2  +  IL-2  -  IL-2  +  IL-2 
cpm/well  ng/ral 
0.8  265 ±  14  468 ±  55  0  73 _+ 40 
1.6  390 ±  28  915 ±  58  3 ±  1.5  73 +  34 
3.1  465 ±  14  1,888 _  330  12 ±  6  156 ±  47 
6.2  2,058 ±  197  7,477 ±  654  27 ±  19  393 ±  38 
12.5  4,150 ±  386  14,609 __. 504  100 ±  40  1,326 ±  316 
25  9,308 +  494  29,325 ±  1,255  240 ±  117  2,647 ±  901 
50  23,051  ±  2,383  44,012 ±  1,995  1,428 ±  700  8,406 ±  1,966 
* Tonsillar B lymphocytes were activated for 2 d with SAC, harvested, and replated at the indicated 
cell densities with 50 U/ml of IL-2. 
* DNA  synthesis was measured by  [3H]thymidine incorporation. A  representative experiment is 
shown; data represent the means ±  SEM of five cultures. 
i IgG production was measured by an enzyme-linked immunosorbent assay.  Means _+ SEM of four 
experiments. 
activation. In addition,  Tac antigen expression was also observed on the surface 
of some EBV-transformed B  cell lines as well as two HTLV-transformed B  cell 
lines. The Tac antigens that were immunoprecipitated from normal activated B 
cells as well as from a  B cell line were shown to have a  molecular weight similar 
to the Tac antigen on PHA-stimulated T  cell blasts. These observations raise the 192  INTERLEUKIN  2  RECEPTORS  ON  HUMAN  B  CELLS 
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FIGURE  7.  (A) Enhancement of proliferation of HS1  cells by recombinant IL-2.  HS1  cells 
(104/well) were cultured with various concentrations of recombinant IL-2 (Re IL-2) from 0.01 
to  10,000  U/ml. Cultures were pulsed with [3H]thymidine (1  vCi/well) over the last 6  h  of a 
72-h culture. Data represent the means ___ SEM of triplicate cultures. (B) Effect of anti-Tac on 
IL-2-induced enhancement of proliferation of HS1  cells. HS1  cells (]04/well) were cultured 
with  100  U/ml of recombinant  IL-2  in  the presence of control ascites P3  (O) or anti-Tac 
ascites (0).  Percent inhibition was determined by [1  -  (b  -  c)/(a  -  c)] x  100, where a  =  cpm 
with  100  U/ml  IL-2,  b  =  cpm  with  IL-2  plus  ascites, c  =  cpm  with  medium  alone.  Data 
represent the means +  SEM of triplicate cultures. 
obvious question of the role of IL-2 in B cell function.  In this  regard,  there is 
considerable controversy about whether  IL-2 in fact has any direct effect on B 
cell function. 
The  opinion  that  IL-2  does not  seem to act directly on  B  cells stems  from 
various lines of evidence. First, activated T  cells respond to IL-2 and grow well 
in in vitro culture, while activated B cells do not respond by proliferation to IL- 
2 and grow poorly in IL-2-containing supernatant (33, 34). Second, B cells and 
B cell blasts cannot absorb IL-2 activity in the murine system (15). Third, highly 
purified IL-2 or IL-2-containing supernatants  from T-T hybridomas have little 
effect on  B  cell  proliferation  in  the  absence  or presence  of polyclonal  B  cell 
activators (35-37).  Fourth, it has been demonstrated (14) that clonal expansion 
and  differentiation  of individual  hapten-specific  B cells require  soluble factors 
distinct from IL-2. Fifth, many investigators have successfully separated IL-2 by 
biochemical procedures from BCGF and BCDF in the murine system (38, 39) as 
well as in the human system (11-13, 35). 
On  the other hand,  in  spite of these observations,  there are  several lines of 
evidence that IL-2 may act directly on B cells. In studies of the synergistic effects 
of cofactors  on  B  cell  function,  depletion  of  IL-2  from  cofactor-containing 
supernatants  by absorption  on  IL-2-dependent  cells also removed factors that 
influence  B  cell  function  (40),  which  suggests  that  IL-2  may  be  one  of the 
cofactors affecting B cell responses. Our recent data also suggested that maximal 
induction of Ig production in in vivo preactivated human B cells can be obtained 
by the  addition  of two kinds  of B  cell  helper  factors plus  IL-2  (Peters  et al., 
manuscript submitted for publication). Thus, the question of the direct effect of 
IL-2 on B cell function has not been completely resolved. MURAGUCHI  ET  AL.  193 
One way to more directly address this issue would be to study the expression 
of IL-2 receptors on B cells. In this regard, Korsmeyer et al. (19) have reported 
recently that Tac antigen is found on hairy cell leukemic cells that also express 
B cell surface markers. They have also shown rearrangement and expression of 
Ig genes in these malignant cells. Since Tac antigen has been reported to be at 
least a  part of the IL-2  receptor (31),  this finding clearly implies that  B  cells 
express IL-2 receptors during a stage of B cell differentiation. 
In  the present study, we have demonstrated by using monoclonal anti-Tac 
antibody that B cells stimulated with polyclonal B cell activators (anti-#, SAC, or 
PMA) stained positively and thus expressed the IL-2 receptor. It is unlikely that 
the staining was nonspecific because control ascites (IgG2a-containing ascites, Ps) 
or the isotype-matched monoclonal antibody OKT3 did not stain those cells. It 
is  also  unlikely that  positively  stained  cells  were  T  cells  because  even  after 
incubation the majority of the cells remained sIg-positive and OKT3-negative. 
Furthermore, immunoprecipitation experiments, either by the surface-labeling 
method  or  the  electrophoretic  transfer  blotting  method,  revealed  that  Tac 
antigens on normal activated B cells had a  molecular weight similar to that of 
the Tac antigens on PHA-stimulated T  cell blasts. 
In a survey of established B cell lines, two out of eight EBV-transformed B cell 
lines were found to be Tac-positive.  Interestingly, the surface charactistics of 
these Tac-positive cell lines revealed that these cells expressed IgD molecules on 
their surface membrane, while other Tac-negative B cell lines lacked sIgD (A. 
Muraguchi, D. J.  Volkman, and A.  S.  Fauci,  unpublished observation).  These 
results suggest that such B cell lines might represent a certain stage of normal B 
cell differentiation because there are several lines of evidence indicating that B 
cells express slgD temporarily during B cell maturation (41, 42). In fact, these 
two B cell lines were found to be capable of responding to T  cell-derived BCDF 
or PMA by enhancing their Ig secretion (D. J.  Volkman, A. S.  Fauci, and A. 
Muraguchi, unpublished observations). 
Two  HTLV-infected  B  cell  lines  were  found  to  be  strongly Tac  positive. 
Among adult T  cell  leukemias, it has been demonstrated (43) that  there is a 
strong correlation between the expression of Tac antigen and the presence of 
HTLV.  Thus,  it  was  felt that  human T  cell leukemias, like  B  cell hairy cell 
leukemia, might result from a transformation-associated activation of a gene for 
expression of the Tac antigen (19).  In this regard, Tac expression on HTLV- 
infected B cells might be a  consequence of HTLV  infection. Alternatively, as 
has been suggested for T  cells (44), the IL-2 receptor on B cells might be the 
binding site for HTLV. If this is the case, we speculate that only activated B cells 
are  targets  for  HTLV  infection.  We  are  now  intensively  investigating  this 
hypothesis. 
The [3H]IL-2 binding study revealed that normal activated B cells and one of 
the HTLV-transformed B cell lines (HS1) had significantly fewer binding sites 
(300-1,000/cell)  compared  with  PHA-T  cell  blasts  (4,000-6,600/ce11)  and 
lower-affinity IL-2  receptors (dissociation constant of 55-460  pM)  compared 
with PHA-T cell blasts (14-26 pM). Furthermore, in these experiments, there 
was a significant difference in the numbers of binding sites as well as the affinities 
of IL-2  receptors between the B  cell  line and  normal activated B  cells.  The 194  INTERLEUKIN  2  RECEPTORS  ON  HUMAN  B  CELLS 
reason for this discrepancy is unclear at present. However, the values of activated 
normal B cells may be underestimated because only a fraction of B cells (-20% 
of cultured B cells) were stained positive with anti-Tac antibody in that experi- 
ment.  An alternative  interpretation  may be that  HS1  cells do not represent  a 
stage of normal B cell activation and thus may bind radiolabeled IL-2 with higher 
affinity than normal activated B cells. 
Finally, we have addressed the question of the functional properties of the IL- 
2 receptors on B cells. Within this context, we have studied the function of IL-2 
receptors on normal  B cells as well as the B cell line using highly purified IL-2 
or recombinant  IL-2. We found that a  moderate concentration of recombinant 
I L-2 (10-50 U/ml) enhanced the proliferation of in vitro-activated B cells and 
relatively high concentrations (100-1,000  U/ml) of I L-2 promoted the growth 
of a  B cell line.  Enhancement  of proliferation  in the B cell line was completely 
blocked by the addition of anti-Tac antibody. Additionally, a moderate concen- 
tration  of IL-2  induced  the  differentiation  of in  vitro  activated  B  cells.  To 
exclude the possibility that IL-2 was mediating its effect solely via contaminating 
T  cells,  we used highly purified  B  cells cultured at low cell  densities.  Even  at 
these densities, distinct increases in DNA synthesis and Ig production were noted 
when IL-2 was present. Thus, a single lymphokine was able to promote both the 
growth and differentiation  of a  population  of normal  activated human  B lym- 
phocytes. These data indicate that IL-2 receptors, when present on B cells, are 
indeed functional. Whether human B cells express IL-2 receptors upon activation 
in vivo is unknown. In this regard, large, presumably in vivo-activated, tonsillar 
B cells are essentially Tac-negative and,  not surprisingly,  poorly responsive to 
IL-2 (Kehri et al., manuscript in preparation). Studies delineating the expression 
of Tac receptors on antigen-activated human B cells and on B cells from patients 
with diseases characterized  by B cell hyperreactivity should be of considerable 
interest. 
Summary 
In  the  present  study,  we  examined  the  expression  of interleukin  2  (IL-2) 
receptors on normal human  B cells as well as established B cell lines.  Anti-Tac 
monoclonal antibody did not bind to freshly separated normal  human  B cells. 
Unexpectedly, with the  appropriate  activation  of the normal  B  cells by anti-~ 
antibody,  phorbol  myristate  acetate,  or Staphylococcus  aureus  Cowan  I  (SAC), 
Tac  antigen  was induced  on  the  activated  B  cells.  Anti-Tac  antibody showed 
consistent reactivity with  two B  cell  lines that  were infected by human  T  cell 
leukemia virus (HTLV) and some reactivity with two out of eight Epstein-Barr 
virus-transformed  B cell lines established from normal adult donors.  Immuno- 
precipitation  analysis  revealed  that  antigens  of similar  size  with  a  molecular 
weight  of  50,000-60,000  can  be  precipitated  with  anti-Tac  antibody  from 
phytohemagglutinin-stimulated normal T  cell blasts and normal activated B cells, 
as well as a cloned B cell line. Binding assays of IL-2 on normal activated B cells 
and on the cloned B cell (HS1) revealed that B cells have significantly fewer sites 
and lower-affinity IL-2 receptors compared with phytohemagglutinin-stimulated 
normal T  cell blasts. Finally, biological properties of the IL-2 receptor on B cells 
were examined by incubating B cells with recombinant  IL-2. It was found that MURAGUCHI  ET AL.  195 
moderate concentrations of IL-2 induce significant enhancement of proliferation 
and differentiation in SAC-activated normal B  cells. These results suggest that 
normal B cells may express functional IL-2 receptors or closely related proteins 
and thus IL-2 may play a significant role in the modulation of B cell function. 
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